CNBC Fast Money
2026-05-01 · Hosted by Melissa Lee · CNBC
Executive Summary
Stocks closed out April with their best month since 2020 (S&P/Nasdaq +~1% to record highs, Dow +800 points, both best month since November 2024 / 2020 respectively). After-hours, Apple beat top and bottom line, missed slightly on iPhone ($56.9B vs. $57.2B est., the second iPhone miss in three quarters), but rallied 3-4% on a Q3 guide of 14-17% YoY revenue growth (well above the 9.5% street estimate). Gross margins beat at 49.3% vs. 48.4% estimate; Greater China was +28% YoY. Eli Lilly soared +10% on results showing 20,000+ patients on its new oral weight-loss pill Foundeo plus a $2B FY guidance raise. Caterpillar hit an all-time high (+10%), MasterCard sold off despite a beat, Roblox cratered (-22%) on safety-driven guidance cut, and Reddit beat across the board. Morgan Stanley’s Mike Wilson stayed bullish, flagging bond volatility — not earnings — as the bigger near-term risk.
Key Stories & Changes
1. Apple Q2 — Beat With Strong Q3 Guide Driving 4% AH Pop
Revenue: $111.2B (beat) — +16%
iPhone: $56.9B (slight miss; supply-constrained) — +22%
Services: $30.98B (record) — +16% (vs. 14% est.)
Greater China: $20.5B — +28%
Gross Margin: 49.3% (beat 48.4%) — Above guidance
Q3 Revenue Guide: +14-17% YoY — vs. 9.5% est.
Q3 Gross Margin Guide: 47.5-48.5% — Includes supply constraints
Tim Cook said iPhone 17 family is the most popular lineup ever
John Ternus (incoming CEO) joined the call, praised Cook, teased “most exciting product and services roadmap” of his 25 years at Apple
Cook said he’s looking forward to a revitalized personalized Siri “this year” — wording suggests not at WWDC June
CFO confirmed expectation of “significantly higher memory costs in fiscal Q3” with bigger impact factored into guidance
Mac segment also supply-constrained; gene Munster: actual growth could exceed 17% guide given Mac constraints
2. Eli Lilly Soars on Weight-Loss Strength
Stock +10% on the day; one of the largest one-day moves for a company of its size
Foundeo (new oral weight-loss pill) now has >20,000 patients taking it (per CEO David Ricks); not factored into Q1 results
Raised FY sales outlook by $2 billion
GLP-1 drugs (Zepbound, Mounjaro) drove $12.9 billion in revenue (~65% of total)
Mizuho’s Jared Holz: street model captured weekly script data 10 days stale — adding 4-5K patients/week reconciles to 20K
Full DTC promotional push for Foundeo coming in Q3
3. Caterpillar — Mega-Cap Industrial Star
Hit all-time high; +10%; responsible for ~500 of Dow’s gains
Beat earnings/revenue, raised annual revenue forecast on power equipment & construction strength
Adding 15 gigawatts of large engine capacity for AI data center power generation
6 projects of 1 GW+ as primary power (not backup) for hyperscalers
4. MasterCard — Beat But Sold Off
Beat earnings, raised FY26 revenue growth outlook
Stock down ~12% YTD; the issue was reporting late vs. Visa rally yesterday
Karen Finerman: “If you liked it before, it’s fine now. Nothing’s changed”
5. Roblox — Cratered on Safety Headwinds
Stock -22% AH
Missed daily active user estimates
Lowered FY guidance: new safety measures slowed new user acquisition
6. Other After-Hours Movers
SNDK: Sandisk — Down despite top/bottom beat — Profit-taking after huge run
WDC: Western Digital — Down despite beat & strong Q4 guide — Same — recent run-up
ROKU: Roku — +higher — Raised annual platform revenue forecast
REDDIT: Reddit — Higher — Beat top/bottom
VEEV: Veeva Systems — Higher — Added to S&P 500 next Thursday
7. Healthcare Movers
Summit Therapeutics: -double digits — delayed PD-1/VEGF cancer trial interim results to H2 2026
Amgen: Beat on sales/EPS, raised FY guidance; Repatha strong, Prolia under biosimilar pressure
Structure Therapeutics (GPCR): Acquisition target view from desk; Karen and Guy added/like it
Novo Nordisk: +5% bounce day but weak YTD; far behind Lilly in GLP-1 race
8. Plexus (PLXS) Earnings — AI Beneficiary
CEO Todd Kelsey on set; stock +70% YTD
Beat top/bottom; healthcare 41%, industrial 41%, A&D the rest
Data center exposure via thermal/power management; recent GE Vernova win
Margin target 6%, planning to raise; commercial aerospace backlog 10+ years
Trends Identified
1. Apple’s AI Re-Rating Opportunity Is Real
Gene Munster and Dan Ives (cited): the gap between Apple’s “incompetent” AI perception and a future “competent” narrative is the single biggest re-rating opportunity in mega-cap tech. Munster cited Google as an analog — they changed the narrative a year ago and got re-rated. Ives quantified the unpriced AI premium at potentially $100/share.
2. Apple Is the Mega-Cap Outlier on CapEx — and That’s a Feature
While the rest of Mag 7 is spending 100%+ of free cash flow on AI build-out (Meta now using debt for $25B), Apple actually decreased CapEx last year. The strategy: let others build the infrastructure, then layer Apple’s “toll” on top via services. The $100B buyback validates the capital-return-first thesis.
3. Mega-Cap Hyperscaler Divergence — Vertical Integration Wins
Josh Brown’s framework: Google and Amazon (vertical, own chips/models/data centers) are pulling away; Meta and Microsoft (reliant on third parties — OpenAI for MSFT, leasing data centers for Meta) are lagging. Six-month performance bears this out.
4. Bond Volatility — Not Earnings — Is the Real Risk
Mike Wilson (Morgan Stanley) argued the earnings story is consensus bullish now, so the marginal risk has shifted to bond volatility. The 10-year sits ~440-450 area; Treasury buybacks and dovish Fed talk capped it in late March. A repeat spike, especially around a leadership transition or anxiety, would matter more than EPS misses.
5. GLP-1 Market Maturing Beyond Top-Line Weight Loss
Mizuho’s Jared Holz: market obsessed with 18-22% weight loss when a clean 10% Amlin oral with no GLP-1 side effects could be a “blockbuster” / “vitamin”-like consumer product. Structure Therapeutics (GPCR) seen as acquisition target for ~$9-10B.
6. Old Economy Recovery Theme via Plexus
Plexus is exemplary of forgotten industrials now seeing demand acceleration — diversified across healthcare, industrial, A&D — with AI exposure via data center thermal/power management as bonus. —-
Sentiment Analysis
Overall Market Sentiment: Bullish
Records on multiple indices, best month in 5+ years, but desk noted the recovery’s pace leaves room for short-term breather. Apple finally getting credit; AI narrative intact.
Risk Factors Highlighted
Apple Memory Cost Pressure in Fiscal Q3: Cook explicitly warned of “significantly higher memory costs” — though guidance includes the impact, magnitude could surprise
Apple AI Delivery Timeline: Cook’s wording on Siri (“this year” not WWDC) suggests delay risk for the AI narrative catalyst
Bond Volatility Spiking Again: Wilson sees this as the biggest market risk; could trigger 5-15% correction if it returns
Iran War / Oil Tail Risk: Trump being briefed on potential military action; oil reversed from 4-year highs but tail remains
Meta CapEx ROI Uncertainty: 50% of 2026 revenue going to spend; debt-funded; ROI unclear
Mag 7 Diverging — Risk to Microsoft / Meta: Vertical integration thesis penalizing those reliant on third parties
Roblox Safety Drag on User Acquisition: Lowered FY guidance signals broader content moderation cost pressure
Summit Therapeutics Trial Delay: PD-1/VEGF interim results pushed to H2 2026 — near-term setback for cancer combo thesis
Apple Capital Allocation Language Shift: Subtle change emphasizing “business needs come ahead” of capital return — opens question of CapEx race
Sandisk/WDC Profit-Taking After Massive Run: Sandisk +73% MTD, +1000% over 12 months — risk of mean reversion despite strong fundamentals
This episode was covered in today’s The Market Signal — 2026-05-01, a cross-source synthesis of multiple podcast reports.